Business
Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing
Wasatch BioLabs (WBL), a leader in native, long-read sequencing and epigenomic analysis, today announced a co-marketing agreement with Agilent Technologies to support the adoption of its Direct Targeted Methylation Sequencing (dTMS) platform. The collaboration brings together Agilent's enrichment chemistries—SureSelect for genomic DNA and Avida for cell-free DNA—and WBL's proprietary Oxford Nanopore-based native-read workflow, expanding access to scalable targeted multi-omic analysis for RUO and
About this update from Agilent Technologies, Inc.
[{"type":"text","content":"SALT LAKE CITY, Dec. 19, 2025 /PRNewswire/ -- Wasatch BioLabs (WBL), a leader in native, long-read sequencing and epigenomic analysis, today announced a co-marketing agreement with Agilent Technologies to support the adoption of its Direct Targeted Methylation Sequencing (dTMS) platform. The collaboration brings together Agilent's enrichment chemistries—SureSelect for genomic DNA and Avida for cell-free DNA—and WBL's proprietary Oxford Nanopore-based native-read workflow, expanding access to scalable targeted multi-omic analysis for RUO and clinical research studies.","length":581,"tagName":"p"},{"type":"image","alt":"Wasatch BioLabs Logo (PRNewsfoto/Wasatch BioLabs)","displaySize":"","headline":null,"caption":"Wasatch BioLabs Logo (PRNewsfoto/Wasatch BioLabs)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":48,"url":"https://media.zenfs.com/en/prnewswire.com/f2fe6e0ac6f0848ea1b9a546a861a29c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/R1nzmBv4WasqXt81fm77hA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTg1O2NmPXdlYnA-/https://media.zenfs.com/en/prnewswire.com/f2fe6e0ac6f0848ea1b9a546a861a29c","width":400,"height":48}},"href":"https://mma.prnewswire.com/media/2338213/Wasatch_BioLabs_Logo_01.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The SureSelect and Avida capabilities both fill a critical gap in native-read sequencing by enabling precise, custom targeting up to 1 Mb, while preserving native DNA features such as methylation and structural variants. By eliminating off-target sequencing, DNA damage of traditional bisulfite-based methods, and biases introduced by PCR amplification, researchers can capture true biology across large and short, customized genomic regions. This opens new doors for liquid biopsy and targeted genomic applications with cost-efficient, scalable, and highly precise approaches suitable for a broad-array of research and screening applications.","length":643,"tagName":"p"},{"type":"text","content":""Multi-omic biology is essential for understanding disease, but for broad adoption it has to be delivered in a way that scales," said Dean Lilley, Senior Director of Product Development at Wasatch BioLabs. "Our alignment with Agilent ensures that native-read targeted sequencing delivers integrated genetic and epigenetic insight, whi...